MX2011008308A - Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparacion y su aplicacion en terapeutica. - Google Patents
Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparacion y su aplicacion en terapeutica.Info
- Publication number
- MX2011008308A MX2011008308A MX2011008308A MX2011008308A MX2011008308A MX 2011008308 A MX2011008308 A MX 2011008308A MX 2011008308 A MX2011008308 A MX 2011008308A MX 2011008308 A MX2011008308 A MX 2011008308A MX 2011008308 A MX2011008308 A MX 2011008308A
- Authority
- MX
- Mexico
- Prior art keywords
- aza
- spiro
- isoxazol
- group
- pyridin
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 9
- 150000002391 heterocyclic compounds Chemical class 0.000 title abstract 2
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims abstract description 96
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 24
- 150000003839 salts Chemical class 0.000 claims abstract description 23
- 239000002253 acid Substances 0.000 claims abstract description 19
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 10
- 239000001257 hydrogen Substances 0.000 claims abstract description 10
- 125000004093 cyano group Chemical group *C#N 0.000 claims abstract description 9
- 229910052731 fluorine Chemical group 0.000 claims abstract description 9
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims abstract description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims abstract description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims abstract description 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 3
- -1 cinolinyl Chemical group 0.000 claims description 138
- 238000000034 method Methods 0.000 claims description 57
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 43
- 239000002904 solvent Substances 0.000 claims description 42
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 23
- 125000005843 halogen group Chemical group 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 15
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims description 13
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- 238000006243 chemical reaction Methods 0.000 claims description 10
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 10
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 9
- 101000918494 Homo sapiens Fatty-acid amide hydrolase 1 Proteins 0.000 claims description 8
- 239000003814 drug Substances 0.000 claims description 8
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 7
- UVHOGDOUCQFVSB-UHFFFAOYSA-N [7-[4-(trifluoromethyl)pyridin-2-yl]-7-azaspiro[3.5]nonan-2-yl]carbamic acid Chemical compound C1C(NC(=O)O)CC21CCN(C=1N=CC=C(C=1)C(F)(F)F)CC2 UVHOGDOUCQFVSB-UHFFFAOYSA-N 0.000 claims description 7
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 7
- GTCAXTIRRLKXRU-UHFFFAOYSA-N methyl carbamate Chemical compound COC(N)=O GTCAXTIRRLKXRU-UHFFFAOYSA-N 0.000 claims description 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 7
- 125000002971 oxazolyl group Chemical group 0.000 claims description 7
- 230000007170 pathology Effects 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 7
- 125000000335 thiazolyl group Chemical group 0.000 claims description 7
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 6
- AKZWRTCWNXHHFR-PDIZUQLASA-N [(3S)-oxolan-3-yl] N-[(2S,3S)-4-[(5S)-5-benzyl-3-[(2R)-2-carbamoyloxy-2,3-dihydro-1H-inden-1-yl]-4-oxo-3H-pyrrol-5-yl]-3-hydroxy-1-phenylbutan-2-yl]carbamate Chemical compound NC(=O)O[C@@H]1Cc2ccccc2C1C1C=N[C@](C[C@H](O)[C@H](Cc2ccccc2)NC(=O)O[C@H]2CCOC2)(Cc2ccccc2)C1=O AKZWRTCWNXHHFR-PDIZUQLASA-N 0.000 claims description 6
- 230000001154 acute effect Effects 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 238000010992 reflux Methods 0.000 claims description 6
- 125000004306 triazinyl group Chemical group 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- YGVRTFBBAJENRA-UHFFFAOYSA-N CNC(=O)OC1CC2(C1)CCN(CC2)c1ccc2cc(F)ccc2n1 Chemical compound CNC(=O)OC1CC2(C1)CCN(CC2)c1ccc2cc(F)ccc2n1 YGVRTFBBAJENRA-UHFFFAOYSA-N 0.000 claims description 4
- 101100134927 Gallus gallus COR8 gene Proteins 0.000 claims description 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 4
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims description 4
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 125000002541 furyl group Chemical group 0.000 claims description 4
- 125000001188 haloalkyl group Chemical group 0.000 claims description 4
- 125000002883 imidazolyl group Chemical group 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 4
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 claims description 4
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 4
- 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 claims description 4
- 125000001544 thienyl group Chemical group 0.000 claims description 4
- HPRVCJIVFQPETI-UHFFFAOYSA-N (3-carbamoyl-1,2-oxazol-5-yl)methyl N-[6-[4-(trifluoromethyl)pyrimidin-2-yl]-6-azaspiro[2.5]octan-2-yl]carbamate Chemical compound NC(=O)c1cc(COC(=O)NC2CC22CCN(CC2)c2nccc(n2)C(F)(F)F)on1 HPRVCJIVFQPETI-UHFFFAOYSA-N 0.000 claims description 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 3
- YORFJSYZQVJVCQ-UHFFFAOYSA-N [7-(6-fluoroquinolin-2-yl)-7-azaspiro[3.5]nonan-2-yl]carbamic acid Chemical compound C1C(NC(=O)O)CC21CCN(C=1N=C3C=CC(F)=CC3=CC=1)CC2 YORFJSYZQVJVCQ-UHFFFAOYSA-N 0.000 claims description 3
- 230000009471 action Effects 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 238000006254 arylation reaction Methods 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 229910052740 iodine Inorganic materials 0.000 claims description 3
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims description 3
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 claims description 3
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 3
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 3
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 claims description 3
- FTIDGBBOFMKCBY-UHFFFAOYSA-N (3-carbamoyl-1,2-oxazol-5-yl)methyl n-[7-(5-bromopyridin-2-yl)-7-azaspiro[3.5]nonan-2-yl]carbamate Chemical compound O1N=C(C(=O)N)C=C1COC(=O)NC1CC2(CCN(CC2)C=2N=CC(Br)=CC=2)C1 FTIDGBBOFMKCBY-UHFFFAOYSA-N 0.000 claims description 2
- LMRGOHPUZORZNE-UHFFFAOYSA-N (4-carbamoyl-1,3-oxazol-2-yl)methyl n-[7-(6-fluoroquinolin-2-yl)-7-azaspiro[3.5]nonan-2-yl]carbamate Chemical compound NC(=O)C1=COC(COC(=O)NC2CC3(C2)CCN(CC3)C=2N=C3C=CC(F)=CC3=CC=2)=N1 LMRGOHPUZORZNE-UHFFFAOYSA-N 0.000 claims description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 claims description 2
- HEAHLTGDUHXTTO-UHFFFAOYSA-N 1,3-thiazolidine 1,1-dioxide Chemical compound O=S1(=O)CCNC1 HEAHLTGDUHXTTO-UHFFFAOYSA-N 0.000 claims description 2
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 claims description 2
- 125000004180 3-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C(F)=C1[H] 0.000 claims description 2
- FBXGQDUVJBKEAJ-UHFFFAOYSA-N 4h-oxazin-3-one Chemical compound O=C1CC=CON1 FBXGQDUVJBKEAJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000035143 Bacterial infection Diseases 0.000 claims description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 2
- 208000000094 Chronic Pain Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- LBHUSLMDWISSKC-UHFFFAOYSA-N NC(=O)c1cc(COC(=O)NC2CC3(C2)CCN(CC3)c2cc(Cl)ccn2)on1 Chemical compound NC(=O)c1cc(COC(=O)NC2CC3(C2)CCN(CC3)c2cc(Cl)ccn2)on1 LBHUSLMDWISSKC-UHFFFAOYSA-N 0.000 claims description 2
- 206010028813 Nausea Diseases 0.000 claims description 2
- 208000001132 Osteoporosis Diseases 0.000 claims description 2
- 206010063897 Renal ischaemia Diseases 0.000 claims description 2
- 238000006619 Stille reaction Methods 0.000 claims description 2
- 206010046543 Urinary incontinence Diseases 0.000 claims description 2
- 206010047700 Vomiting Diseases 0.000 claims description 2
- VMIXRXRNUMZQJJ-UHFFFAOYSA-N [3-(methylcarbamoyl)-1,2-oxazol-5-yl]methyl N-[6-[4-(trifluoromethyl)pyrimidin-2-yl]-6-azaspiro[2.5]octan-2-yl]carbamate Chemical compound CNC(=O)c1cc(COC(=O)NC2CC22CCN(CC2)c2nccc(n2)C(F)(F)F)on1 VMIXRXRNUMZQJJ-UHFFFAOYSA-N 0.000 claims description 2
- SERVYPFBYXBKBT-UHFFFAOYSA-N [7-(6-chloroquinolin-2-yl)-7-azaspiro[3.5]nonan-2-yl]carbamic acid Chemical compound C1C(NC(=O)O)CC21CCN(C=1N=C3C=CC(Cl)=CC3=CC=1)CC2 SERVYPFBYXBKBT-UHFFFAOYSA-N 0.000 claims description 2
- 208000005298 acute pain Diseases 0.000 claims description 2
- 208000026935 allergic disease Diseases 0.000 claims description 2
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 claims description 2
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 claims description 2
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004604 benzisothiazolyl group Chemical group S1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000004603 benzisoxazolyl group Chemical group O1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 2
- ZADPBFCGQRWHPN-UHFFFAOYSA-N boronic acid Chemical compound OBO ZADPBFCGQRWHPN-UHFFFAOYSA-N 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 239000000460 chlorine Substances 0.000 claims description 2
- 125000000259 cinnolinyl group Chemical group N1=NC(=CC2=CC=CC=C12)* 0.000 claims description 2
- 238000005859 coupling reaction Methods 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 239000002621 endocannabinoid Substances 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 125000004612 furopyridinyl group Chemical group O1C(=CC2=C1C=CC=N2)* 0.000 claims description 2
- 125000004438 haloalkoxy group Chemical group 0.000 claims description 2
- 125000004857 imidazopyridinyl group Chemical group N1C(=NC2=C1C=CC=N2)* 0.000 claims description 2
- 208000026278 immune system disease Diseases 0.000 claims description 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 claims description 2
- 230000002458 infectious effect Effects 0.000 claims description 2
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 claims description 2
- 150000003951 lactams Chemical class 0.000 claims description 2
- 230000008693 nausea Effects 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 230000000926 neurological effect Effects 0.000 claims description 2
- LKZKGRRDUWVNSR-UHFFFAOYSA-N oxazepin-3-one Chemical compound O=C1NOC=CC=C1 LKZKGRRDUWVNSR-UHFFFAOYSA-N 0.000 claims description 2
- SFJGCXYXEFWEBK-UHFFFAOYSA-N oxazepine Chemical compound O1C=CC=CC=N1 SFJGCXYXEFWEBK-UHFFFAOYSA-N 0.000 claims description 2
- 230000002685 pulmonary effect Effects 0.000 claims description 2
- 208000019116 sleep disease Diseases 0.000 claims description 2
- 239000000758 substrate Substances 0.000 claims description 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims description 2
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 claims description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
- 125000004001 thioalkyl group Chemical group 0.000 claims description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 claims description 2
- 229910052723 transition metal Inorganic materials 0.000 claims description 2
- 150000003624 transition metals Chemical class 0.000 claims description 2
- 125000001425 triazolyl group Chemical group 0.000 claims description 2
- 125000002827 triflate group Chemical group FC(S(=O)(=O)O*)(F)F 0.000 claims description 2
- 230000003612 virological effect Effects 0.000 claims description 2
- 230000008673 vomiting Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- AGNORYIPLDYPDF-UHFFFAOYSA-N (3-carbamoyl-1,2-oxazol-5-yl)methyl n-[7-(6-fluoroquinolin-2-yl)-7-azaspiro[3.5]nonan-2-yl]carbamate Chemical compound O1N=C(C(=O)N)C=C1COC(=O)NC1CC2(CCN(CC2)C=2N=C3C=CC(F)=CC3=CC=2)C1 AGNORYIPLDYPDF-UHFFFAOYSA-N 0.000 claims 1
- CGRPCIAJCFRPPD-UHFFFAOYSA-N NC(=O)c1cc(COC(=O)NC2CC3(C2)CCN(CC3)c2cc(ccn2)C(F)(F)F)on1 Chemical compound NC(=O)c1cc(COC(=O)NC2CC3(C2)CCN(CC3)c2cc(ccn2)C(F)(F)F)on1 CGRPCIAJCFRPPD-UHFFFAOYSA-N 0.000 claims 1
- 208000030852 Parasitic disease Diseases 0.000 claims 1
- JZFICWYCTCCINF-UHFFFAOYSA-N Thiadiazin Chemical compound S=C1SC(C)NC(C)N1CCN1C(=S)SC(C)NC1C JZFICWYCTCCINF-UHFFFAOYSA-N 0.000 claims 1
- 208000012886 Vertigo Diseases 0.000 claims 1
- DUBPMYSYASRVMR-UHFFFAOYSA-N [3-(methylcarbamoyl)-1,2-oxazol-5-yl]methyl n-[2-(6-fluoroquinolin-2-yl)-2-azaspiro[3.3]heptan-6-yl]carbamate Chemical compound O1N=C(C(=O)NC)C=C1COC(=O)NC1CC2(CN(C2)C=2N=C3C=CC(F)=CC3=CC=2)C1 DUBPMYSYASRVMR-UHFFFAOYSA-N 0.000 claims 1
- DHVJATMZGLAJBR-UHFFFAOYSA-N [6-(5-bromopyridin-2-yl)-6-azaspiro[3.4]octan-2-yl]carbamic acid Chemical compound C1C(NC(=O)O)CC21CN(C=1N=CC(Br)=CC=1)CC2 DHVJATMZGLAJBR-UHFFFAOYSA-N 0.000 claims 1
- XLRQGVSRYGUZBK-UHFFFAOYSA-N [6-[4-(trifluoromethyl)pyridin-2-yl]-6-azaspiro[3.4]octan-2-yl]carbamic acid Chemical compound C1C(NC(=O)O)CC21CN(C=1N=CC=C(C=1)C(F)(F)F)CC2 XLRQGVSRYGUZBK-UHFFFAOYSA-N 0.000 claims 1
- YDXGWEIAMDECPY-UHFFFAOYSA-N [7-(6-chloroquinolin-2-yl)-7-azaspiro[3.5]nonan-2-yl]methylcarbamic acid Chemical compound C1C(CNC(=O)O)CC21CCN(C=1N=C3C=CC(Cl)=CC3=CC=1)CC2 YDXGWEIAMDECPY-UHFFFAOYSA-N 0.000 claims 1
- KEEMJVWCORELOG-UHFFFAOYSA-N [7-[5-(trifluoromethyl)pyridin-2-yl]-7-azaspiro[3.5]nonan-2-yl]carbamic acid Chemical compound C1C(NC(=O)O)CC21CCN(C=1N=CC(=CC=1)C(F)(F)F)CC2 KEEMJVWCORELOG-UHFFFAOYSA-N 0.000 claims 1
- ZANGIMKRYVOONN-UHFFFAOYSA-N [7-[6-(4-fluorophenyl)pyrazin-2-yl]-7-azaspiro[3.5]nonan-2-yl]carbamic acid Chemical compound C1C(NC(=O)O)CC21CCN(C=1N=C(C=NC=1)C=1C=CC(F)=CC=1)CC2 ZANGIMKRYVOONN-UHFFFAOYSA-N 0.000 claims 1
- 231100000889 vertigo Toxicity 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract description 2
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 233
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 196
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 111
- 239000000047 product Substances 0.000 description 88
- 238000005481 NMR spectroscopy Methods 0.000 description 72
- 239000000243 solution Substances 0.000 description 61
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 56
- 239000000203 mixture Substances 0.000 description 52
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 51
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 41
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 40
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 38
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 34
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 31
- 238000001704 evaporation Methods 0.000 description 31
- 239000012074 organic phase Substances 0.000 description 31
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 30
- 238000004587 chromatography analysis Methods 0.000 description 29
- 229910052938 sodium sulfate Inorganic materials 0.000 description 28
- 235000011152 sodium sulphate Nutrition 0.000 description 28
- 239000000843 powder Substances 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 26
- 239000008346 aqueous phase Substances 0.000 description 26
- 239000000741 silica gel Substances 0.000 description 26
- 229910002027 silica gel Inorganic materials 0.000 description 26
- 239000007864 aqueous solution Substances 0.000 description 25
- 229920006395 saturated elastomer Polymers 0.000 description 25
- 239000012429 reaction media Substances 0.000 description 24
- 239000003921 oil Substances 0.000 description 23
- 235000019198 oils Nutrition 0.000 description 23
- 239000000706 filtrate Substances 0.000 description 22
- 230000008020 evaporation Effects 0.000 description 21
- 229910021529 ammonia Inorganic materials 0.000 description 19
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 18
- 238000000746 purification Methods 0.000 description 17
- 239000007787 solid Substances 0.000 description 17
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 235000019270 ammonium chloride Nutrition 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N dimethylformamide Substances CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 238000003756 stirring Methods 0.000 description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 239000002585 base Substances 0.000 description 10
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 8
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 8
- 102100029111 Fatty-acid amide hydrolase 1 Human genes 0.000 description 8
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 8
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 8
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 7
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 7
- NXLNNXIXOYSCMB-UHFFFAOYSA-N (4-nitrophenyl) carbonochloridate Chemical compound [O-][N+](=O)C1=CC=C(OC(Cl)=O)C=C1 NXLNNXIXOYSCMB-UHFFFAOYSA-N 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 6
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 6
- 239000011541 reaction mixture Substances 0.000 description 6
- 229910052708 sodium Inorganic materials 0.000 description 6
- 239000011734 sodium Substances 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
- UTFRYMCWPOVSSJ-UHFFFAOYSA-N 2-methylsulfonyloxy-6-azaspiro[3.4]octane-6-carboxylic acid Chemical compound C1C(OS(=O)(=O)C)CC21CN(C(O)=O)CC2 UTFRYMCWPOVSSJ-UHFFFAOYSA-N 0.000 description 5
- LBUNNMJLXWQQBY-UHFFFAOYSA-N 4-fluorophenylboronic acid Chemical compound OB(O)C1=CC=C(F)C=C1 LBUNNMJLXWQQBY-UHFFFAOYSA-N 0.000 description 5
- MYUQKYGWKHTRPG-UHFFFAOYSA-N 5-bromo-2-fluoropyridine Chemical compound FC1=CC=C(Br)C=N1 MYUQKYGWKHTRPG-UHFFFAOYSA-N 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 5
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 5
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 5
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 5
- 229910000024 caesium carbonate Inorganic materials 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 5
- 239000011981 lindlar catalyst Substances 0.000 description 5
- 239000012047 saturated solution Substances 0.000 description 5
- 239000012453 solvate Substances 0.000 description 5
- DVMMLLQNKHYJSA-UHFFFAOYSA-N 2-(aminomethyl)-6-azaspiro[3.4]octane-6-carboxylic acid Chemical compound C1C(CN)CC21CN(C(O)=O)CC2 DVMMLLQNKHYJSA-UHFFFAOYSA-N 0.000 description 4
- LQUCPHNWLJMLAK-UHFFFAOYSA-N 2-amino-6-azaspiro[3.4]octane-6-carboxylic acid Chemical compound C1C(N)CC21CN(C(O)=O)CC2 LQUCPHNWLJMLAK-UHFFFAOYSA-N 0.000 description 4
- ZVRPXABGMKBROG-UHFFFAOYSA-N 2-fluoro-5-(4-fluorophenyl)pyridine Chemical compound C1=CC(F)=CC=C1C1=CC=C(F)N=C1 ZVRPXABGMKBROG-UHFFFAOYSA-N 0.000 description 4
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 4
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 4
- 239000007868 Raney catalyst Substances 0.000 description 4
- 229910000564 Raney nickel Inorganic materials 0.000 description 4
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- XFVSARIHJBMGIX-UHFFFAOYSA-N [3-(methylcarbamoyl)-1,2-oxazol-5-yl]methyl (4-nitrophenyl) carbonate Chemical compound O1N=C(C(=O)NC)C=C1COC(=O)OC1=CC=C([N+]([O-])=O)C=C1 XFVSARIHJBMGIX-UHFFFAOYSA-N 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- WPUZVACHJLCNEI-UHFFFAOYSA-N (6-carboxy-6-azaspiro[3.4]octan-2-yl)-diazonioazanide Chemical compound C1N(C(=O)O)CCC11CC([N-][N+]#N)C1 WPUZVACHJLCNEI-UHFFFAOYSA-N 0.000 description 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 description 3
- ONAXLFXUZJRXMX-UHFFFAOYSA-N 2-amino-7-azaspiro[3.5]nonane-7-carboxylic acid Chemical compound C1C(N)CC21CCN(C(O)=O)CC2 ONAXLFXUZJRXMX-UHFFFAOYSA-N 0.000 description 3
- GEDXYXFMKSPTLS-UHFFFAOYSA-N 2-bromo-6-fluoroquinoline Chemical compound N1=C(Br)C=CC2=CC(F)=CC=C21 GEDXYXFMKSPTLS-UHFFFAOYSA-N 0.000 description 3
- CACIAMRXJXVWNS-UHFFFAOYSA-N 5-(hydroxymethyl)-1,2-oxazole-3-carboxamide Chemical compound NC(=O)C=1C=C(CO)ON=1 CACIAMRXJXVWNS-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 125000001931 aliphatic group Chemical group 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000003054 catalyst Substances 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 239000012230 colorless oil Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000006911 enzymatic reaction Methods 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 208000002551 irritable bowel syndrome Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 3
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 description 3
- 239000011535 reaction buffer Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- LATFAUUEAROCTR-UHFFFAOYSA-N 2-(aminomethyl)-7-azaspiro[3.5]nonane-7-carboxylic acid Chemical compound C1C(CN)CC21CCN(C(O)=O)CC2 LATFAUUEAROCTR-UHFFFAOYSA-N 0.000 description 2
- ICWLFLLMWWPZAM-UHFFFAOYSA-N 2-(ethoxycarbonylamino)-7-azaspiro[3.5]nonane-7-carboxylic acid Chemical compound C1C(NC(=O)OCC)CC21CCN(C(O)=O)CC2 ICWLFLLMWWPZAM-UHFFFAOYSA-N 0.000 description 2
- RCRCTBLIHCHWDZ-UHFFFAOYSA-N 2-Arachidonoyl Glycerol Chemical compound CCCCCC=CCC=CCC=CCC=CCCCC(=O)OC(CO)CO RCRCTBLIHCHWDZ-UHFFFAOYSA-N 0.000 description 2
- QUTXMPNJUXEBAZ-UHFFFAOYSA-N 2-azido-7-[5-(4-fluorophenyl)pyridin-2-yl]-7-azaspiro[3.5]nonane Chemical compound C1=CC(F)=CC=C1C1=CC=C(N2CCC3(CC(C3)N=[N+]=[N-])CC2)N=C1 QUTXMPNJUXEBAZ-UHFFFAOYSA-N 0.000 description 2
- VDDVBQFECLESDM-UHFFFAOYSA-N 2-cyano-6-azaspiro[3.4]octane-6-carboxylic acid Chemical compound C1N(C(=O)O)CCC11CC(C#N)C1 VDDVBQFECLESDM-UHFFFAOYSA-N 0.000 description 2
- DMUXSGAKEXSNGN-UHFFFAOYSA-N 2-ethyloctanoic acid Chemical compound CCCCCCC(CC)C(O)=O DMUXSGAKEXSNGN-UHFFFAOYSA-N 0.000 description 2
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- AHRJXSOIEPUORI-UHFFFAOYSA-N 6-oxo-2-azaspiro[3.3]heptane-2-carboxylic acid Chemical compound C1N(C(=O)O)CC21CC(=O)C2 AHRJXSOIEPUORI-UHFFFAOYSA-N 0.000 description 2
- ANACBSKBLCACPV-UHFFFAOYSA-N 7-(5-bromopyridin-2-yl)-7-azaspiro[3.5]nonan-2-ol Chemical compound C1C(O)CC21CCN(C=1N=CC(Br)=CC=1)CC2 ANACBSKBLCACPV-UHFFFAOYSA-N 0.000 description 2
- JQLJWUFAJHHHMP-UHFFFAOYSA-N 7-[5-(4-fluorophenyl)pyridin-2-yl]-7-azaspiro[3.5]nonan-2-amine Chemical compound C1C(N)CC21CCN(C=1N=CC(=CC=1)C=1C=CC(F)=CC=1)CC2 JQLJWUFAJHHHMP-UHFFFAOYSA-N 0.000 description 2
- ACABZOPFWZTUMU-UHFFFAOYSA-N 7-[5-(4-fluorophenyl)pyridin-2-yl]-7-azaspiro[3.5]nonan-2-ol Chemical compound C1C(O)CC21CCN(C=1N=CC(=CC=1)C=1C=CC(F)=CC=1)CC2 ACABZOPFWZTUMU-UHFFFAOYSA-N 0.000 description 2
- OOVWDRMHPAEWPC-UHFFFAOYSA-N 7-azaspiro[3.5]nonan-2-yl-[[3-(methylcarbamoyl)-1,2-oxazol-5-yl]methyl]carbamic acid;hydrochloride Chemical compound Cl.O1N=C(C(=O)NC)C=C1CN(C(O)=O)C1CC2(CCNCC2)C1 OOVWDRMHPAEWPC-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- HQUHXCZYYSSGRY-UHFFFAOYSA-N Cl.C1C(CC12CCNCC2)NC(OCC)=O Chemical compound Cl.C1C(CC12CCNCC2)NC(OCC)=O HQUHXCZYYSSGRY-UHFFFAOYSA-N 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- 208000011231 Crohn disease Diseases 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 101000937693 Homo sapiens Fatty acid 2-hydroxylase Proteins 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 201000002661 Spondylitis Diseases 0.000 description 2
- LNGCKTHHAGVEQX-UHFFFAOYSA-N [2-(6-fluoroquinolin-2-yl)-2-azaspiro[3.3]heptan-6-yl]carbamic acid Chemical compound C1C(NC(=O)O)CC21CN(C=1N=C3C=CC(F)=CC3=CC=1)C2 LNGCKTHHAGVEQX-UHFFFAOYSA-N 0.000 description 2
- FQZMSWJBVDKYAF-UHFFFAOYSA-N [3-(methylcarbamoyl)-1,2-oxazol-5-yl]methyl n-[7-(6-fluoroquinolin-2-yl)-7-azaspiro[3.5]nonan-2-yl]carbamate Chemical compound O1N=C(C(=O)NC)C=C1COC(=O)NC1CC2(CCN(CC2)C=2N=C3C=CC(F)=CC3=CC=2)C1 FQZMSWJBVDKYAF-UHFFFAOYSA-N 0.000 description 2
- QAXQHODMJKVDEM-UHFFFAOYSA-N [6-[5-(4-fluorophenyl)pyridin-2-yl]-6-azaspiro[3.4]octan-2-yl]carbamic acid Chemical compound C1C(NC(=O)O)CC21CN(C=1N=CC(=CC=1)C=1C=CC(F)=CC=1)CC2 QAXQHODMJKVDEM-UHFFFAOYSA-N 0.000 description 2
- NDQMWZFPVCCGAZ-UHFFFAOYSA-N [7-[5-(4-fluorophenyl)pyridin-2-yl]-7-azaspiro[3.5]nonan-2-yl]carbamic acid Chemical compound C1C(NC(=O)O)CC21CCN(C=1N=CC(=CC=1)C=1C=CC(F)=CC=1)CC2 NDQMWZFPVCCGAZ-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- SFQFQELBHQHAAW-UHFFFAOYSA-N benzyl 3-(1,3-thiazol-4-ylmethoxycarbonylamino)-7-azaspiro[3.5]nonane-7-carboxylate Chemical compound C1CC2(C1NC(=O)OCC3=CSC=N3)CCN(CC2)C(=O)OCC4=CC=CC=C4 SFQFQELBHQHAAW-UHFFFAOYSA-N 0.000 description 2
- VQRISUCDOHFQLC-UHFFFAOYSA-N benzyl N-[6-[4-(trifluoromethyl)pyrimidin-2-yl]-6-azaspiro[2.5]octan-2-yl]carbamate Chemical compound C(C1=CC=CC=C1)OC(NC1CC11CCN(CC1)C1=NC=CC(=N1)C(F)(F)F)=O VQRISUCDOHFQLC-UHFFFAOYSA-N 0.000 description 2
- SJKOSZLPNOBVKQ-UHFFFAOYSA-N benzyl n-(6-azaspiro[2.5]octan-2-yl)carbamate Chemical compound C=1C=CC=CC=1COC(=O)NC1CC11CCNCC1 SJKOSZLPNOBVKQ-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- YMESHTODKWRGND-UHFFFAOYSA-N ethyl 5-(6-azaspiro[3.4]octan-2-ylcarbamoyloxymethyl)-1,2-oxazole-3-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.O1N=C(C(=O)OCC)C=C1COC(=O)NC1CC2(CNCC2)C1 YMESHTODKWRGND-UHFFFAOYSA-N 0.000 description 2
- ZWVVVEYXDQMHGQ-UHFFFAOYSA-N ethyl 5-(hydroxymethyl)-1,2-oxazole-3-carboxylate Chemical compound CCOC(=O)C=1C=C(CO)ON=1 ZWVVVEYXDQMHGQ-UHFFFAOYSA-N 0.000 description 2
- CNEBKOJXRNJEEX-UHFFFAOYSA-N ethyl N-[7-(6-chloroquinolin-2-yl)-7-azaspiro[3.5]nonan-2-yl]carbamate Chemical compound C(C)OC(NC1CC2(C1)CCN(CC2)C1=NC2=CC=C(C=C2C=C1)Cl)=O CNEBKOJXRNJEEX-UHFFFAOYSA-N 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 208000004296 neuralgia Diseases 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 201000008482 osteoarthritis Diseases 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- IVDFJHOHABJVEH-UHFFFAOYSA-N pinacol Chemical compound CC(C)(O)C(C)(C)O IVDFJHOHABJVEH-UHFFFAOYSA-N 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- DYWSVUBJGFTOQC-UHFFFAOYSA-N xi-2-Ethylheptanoic acid Chemical compound CCCCCC(CC)C(O)=O DYWSVUBJGFTOQC-UHFFFAOYSA-N 0.000 description 2
- PIFPEOIFYCDCNA-TXSOCPGVSA-N (2s,3s)-2-[[(2s)-2-[[(2s)-1-[(2s)-2-[[(2s)-2-[[(2s)-1-[(2s)-6-amino-2-[[(2s)-4-amino-2-[[2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-4-carboxybutanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]acetyl]amino]-4-oxobutanoyl]amino]hexanoyl]pyr Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 PIFPEOIFYCDCNA-TXSOCPGVSA-N 0.000 description 1
- DQKNFOBANMFOCP-UHFFFAOYSA-N (3-carbamoyl-1,2-oxazol-5-yl)methyl n-[7-[5-(4-fluorophenyl)pyridin-2-yl]-7-azaspiro[3.5]nonan-2-yl]carbamate Chemical compound O1N=C(C(=O)N)C=C1COC(=O)NC1CC2(CCN(CC2)C=2N=CC(=CC=2)C=2C=CC(F)=CC=2)C1 DQKNFOBANMFOCP-UHFFFAOYSA-N 0.000 description 1
- TZFXXBVTDMNGHY-UHFFFAOYSA-N (3-carbamoyl-1,2-oxazol-5-yl)methyl n-[7-[5-(trifluoromethyl)pyridin-2-yl]-7-azaspiro[3.5]nonan-2-yl]carbamate Chemical compound O1N=C(C(=O)N)C=C1COC(=O)NC1CC2(CCN(CC2)C=2N=CC(=CC=2)C(F)(F)F)C1 TZFXXBVTDMNGHY-UHFFFAOYSA-N 0.000 description 1
- CMKSGOMYRWZDEQ-UHFFFAOYSA-N (4-nitrophenyl) 1,3-thiazol-4-ylmethyl carbonate Chemical compound C1=CC([N+](=O)[O-])=CC=C1OC(=O)OCC1=CSC=N1 CMKSGOMYRWZDEQ-UHFFFAOYSA-N 0.000 description 1
- LKYNGTHMKCTTQC-UHFFFAOYSA-N 1,2-oxazole-3-carboxamide Chemical compound NC(=O)C=1C=CON=1 LKYNGTHMKCTTQC-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- ZHXUWDPHUQHFOV-UHFFFAOYSA-N 2,5-dibromopyridine Chemical compound BrC1=CC=C(Br)N=C1 ZHXUWDPHUQHFOV-UHFFFAOYSA-N 0.000 description 1
- LPDFGLZUUCLXGM-UHFFFAOYSA-N 2,6-dichloroquinoline Chemical compound N1=C(Cl)C=CC2=CC(Cl)=CC=C21 LPDFGLZUUCLXGM-UHFFFAOYSA-N 0.000 description 1
- RWWBVGAFHRRRBG-UHFFFAOYSA-N 2-(phenylmethoxycarbonylamino)-6-azaspiro[2.5]octane-6-carboxylic acid Chemical compound C1CN(C(=O)O)CCC11C(NC(=O)OCC=2C=CC=CC=2)C1 RWWBVGAFHRRRBG-UHFFFAOYSA-N 0.000 description 1
- MDARRYBMOOYMAF-UHFFFAOYSA-N 2-[(4-nitrophenoxy)carbonylamino]-7-azaspiro[3.5]nonane-7-carboxylic acid Chemical compound C1CN(C(=O)O)CCC11CC(NC(=O)OC=2C=CC(=CC=2)[N+]([O-])=O)C1 MDARRYBMOOYMAF-UHFFFAOYSA-N 0.000 description 1
- HPFXIVZBQYQGKL-UHFFFAOYSA-N 2-[7-(5-bromopyridin-2-yl)-7-azaspiro[3.5]nonan-2-yl]ethyl carbamate Chemical compound C(N)(OCCC1CC2(C1)CCN(CC2)C1=NC=C(C=C1)Br)=O HPFXIVZBQYQGKL-UHFFFAOYSA-N 0.000 description 1
- GBWMDDXBFNCDIH-UHFFFAOYSA-N 2-[[(3-carbamoyl-1,2-oxazol-5-yl)methoxycarbonylamino]methyl]-7-azaspiro[3.5]nonane-7-carboxylic acid Chemical compound O1N=C(C(=O)N)C=C1COC(=O)NCC1CC2(CCN(CC2)C(O)=O)C1 GBWMDDXBFNCDIH-UHFFFAOYSA-N 0.000 description 1
- CICHKYHXZODNOT-UHFFFAOYSA-N 2-[[3-(methylcarbamoyl)-1,2-oxazol-5-yl]methoxycarbonylamino]-7-azaspiro[3.5]nonane-7-carboxylic acid Chemical compound O1N=C(C(=O)NC)C=C1COC(=O)NC1CC2(CCN(CC2)C(O)=O)C1 CICHKYHXZODNOT-UHFFFAOYSA-N 0.000 description 1
- OVELUDXHJFZYLJ-UHFFFAOYSA-N 2-[[[3-(methylcarbamoyl)-1,2-oxazol-5-yl]methoxycarbonylamino]methyl]-6-azaspiro[3.4]octane-6-carboxylic acid Chemical compound O1N=C(C(=O)NC)C=C1COC(=O)NCC1CC2(CN(CC2)C(O)=O)C1 OVELUDXHJFZYLJ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- YSUIQYOGTINQIN-UZFYAQMZSA-N 2-amino-9-[(1S,6R,8R,9S,10R,15R,17R,18R)-8-(6-aminopurin-9-yl)-9,18-difluoro-3,12-dihydroxy-3,12-bis(sulfanylidene)-2,4,7,11,13,16-hexaoxa-3lambda5,12lambda5-diphosphatricyclo[13.2.1.06,10]octadecan-17-yl]-1H-purin-6-one Chemical compound NC1=NC2=C(N=CN2[C@@H]2O[C@@H]3COP(S)(=O)O[C@@H]4[C@@H](COP(S)(=O)O[C@@H]2[C@@H]3F)O[C@H]([C@H]4F)N2C=NC3=C2N=CN=C3N)C(=O)N1 YSUIQYOGTINQIN-UZFYAQMZSA-N 0.000 description 1
- OHYOJULVATXPSZ-UHFFFAOYSA-N 2-azaspiro[3.3]heptane-2-carboxylic acid Chemical compound C1N(C(=O)O)CC11CCC1 OHYOJULVATXPSZ-UHFFFAOYSA-N 0.000 description 1
- FZRBTBCCMVNZBD-UHFFFAOYSA-N 2-chloro-4-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=CC=NC(Cl)=N1 FZRBTBCCMVNZBD-UHFFFAOYSA-N 0.000 description 1
- USAYWGMYCNWTGO-UHFFFAOYSA-N 2-chloro-6-fluoroquinoline Chemical compound N1=C(Cl)C=CC2=CC(F)=CC=C21 USAYWGMYCNWTGO-UHFFFAOYSA-N 0.000 description 1
- BQXQDUYPSUIEAU-UHFFFAOYSA-N 2-hydroxy-6-azaspiro[3.4]octane-6-carboxylic acid Chemical compound C1C(O)CC21CN(C(O)=O)CC2 BQXQDUYPSUIEAU-UHFFFAOYSA-N 0.000 description 1
- QHQIKZCNLZUGKH-UHFFFAOYSA-N 2-hydroxyimino-7-azaspiro[3.5]nonane-7-carboxylic acid Chemical compound C1C(=NO)CC21CCN(C(O)=O)CC2 QHQIKZCNLZUGKH-UHFFFAOYSA-N 0.000 description 1
- FWJRSOGVYOIVOC-UHFFFAOYSA-N 2-methylprop-1-enylboronic acid Chemical compound CC(C)=CB(O)O FWJRSOGVYOIVOC-UHFFFAOYSA-N 0.000 description 1
- FATIWVGOGUQZGL-UHFFFAOYSA-N 2-oxo-6-azaspiro[3.4]octane-6-carboxylic acid Chemical compound C1N(C(=O)O)CCC11CC(=O)C1 FATIWVGOGUQZGL-UHFFFAOYSA-N 0.000 description 1
- RLQZIECDMISZHS-UHFFFAOYSA-N 2-phenylcyclohexa-2,5-diene-1,4-dione Chemical compound O=C1C=CC(=O)C(C=2C=CC=CC=2)=C1 RLQZIECDMISZHS-UHFFFAOYSA-N 0.000 description 1
- JWBLHEQJANYLQY-UHFFFAOYSA-N 3-methylideneazetidine-1-carboxylic acid Chemical compound OC(=O)N1CC(=C)C1 JWBLHEQJANYLQY-UHFFFAOYSA-N 0.000 description 1
- RHMPLDJJXGPMEX-UHFFFAOYSA-N 4-fluorophenol Chemical compound OC1=CC=C(F)C=C1 RHMPLDJJXGPMEX-UHFFFAOYSA-N 0.000 description 1
- NUNULGLALWOMKB-UHFFFAOYSA-N 5-(hydroxymethyl)-n-methyl-1,2-oxazole-3-carboxamide Chemical compound CNC(=O)C=1C=C(CO)ON=1 NUNULGLALWOMKB-UHFFFAOYSA-N 0.000 description 1
- VIQGDXYPPXUNFP-UHFFFAOYSA-N 6-[(3-ethoxycarbonyl-1,2-oxazol-5-yl)methoxycarbonylamino]-2-azaspiro[3.3]heptane-2-carboxylic acid Chemical compound O1N=C(C(=O)OCC)C=C1COC(=O)NC1CC2(CN(C2)C(O)=O)C1 VIQGDXYPPXUNFP-UHFFFAOYSA-N 0.000 description 1
- ITXAUJJUOXDDPT-UHFFFAOYSA-N 6-[4-(trifluoromethyl)pyrimidin-2-yl]-6-azaspiro[2.5]octan-2-amine Chemical compound NC1CC11CCN(C=2N=C(C=CN=2)C(F)(F)F)CC1 ITXAUJJUOXDDPT-UHFFFAOYSA-N 0.000 description 1
- MPAQGNXNNJFYRB-UHFFFAOYSA-N 6-azaspiro[2.5]octane-2,6-dicarboxylic acid Chemical compound OC(=O)C1CC11CCN(C(O)=O)CC1 MPAQGNXNNJFYRB-UHFFFAOYSA-N 0.000 description 1
- NVZWMJWMTWOVNJ-UHFFFAOYSA-N 6-azaspiro[3.4]octane Chemical compound C1CCC21CNCC2 NVZWMJWMTWOVNJ-UHFFFAOYSA-N 0.000 description 1
- AOSJWPZJQOIPIU-UHFFFAOYSA-N 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylic acid Chemical compound C1C(O)CC21CN(C(O)=O)C2 AOSJWPZJQOIPIU-UHFFFAOYSA-N 0.000 description 1
- SEIQRWMKIZLBSZ-UHFFFAOYSA-N 7,7-dichloro-6-oxo-2-azaspiro[3.3]heptane-2-carboxylic acid Chemical compound C1N(C(=O)O)CC21C(Cl)(Cl)C(=O)C2 SEIQRWMKIZLBSZ-UHFFFAOYSA-N 0.000 description 1
- FITMDQMADGJYGP-UHFFFAOYSA-N 7-(6-chloroquinolin-2-yl)-7-azaspiro[3.5]nonan-2-amine Chemical compound C1C(N)CC21CCN(C=1N=C3C=CC(Cl)=CC3=CC=1)CC2 FITMDQMADGJYGP-UHFFFAOYSA-N 0.000 description 1
- OKZZIRUOTWKYGM-UHFFFAOYSA-N 7-[5-(2-methylpropyl)pyridin-2-yl]-7-azaspiro[3.5]nonan-2-amine Chemical compound N1=CC(CC(C)C)=CC=C1N1CCC2(CC(N)C2)CC1 OKZZIRUOTWKYGM-UHFFFAOYSA-N 0.000 description 1
- UBHOPTMYFRGEFP-UHFFFAOYSA-N 7-azaspiro[3.5]nonan-2-ol;hydrochloride Chemical compound Cl.C1C(O)CC21CCNCC2 UBHOPTMYFRGEFP-UHFFFAOYSA-N 0.000 description 1
- OUXRPSUPWKNBLL-UHFFFAOYSA-N 7-azaspiro[3.5]nonane-2-carbonitrile Chemical compound C1C(C#N)CC21CCNCC2 OUXRPSUPWKNBLL-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 229910000497 Amalgam Inorganic materials 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 201000006474 Brain Ischemia Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- GLSUNYRWHLQJSV-UHFFFAOYSA-N C1CNCCC12CC(C2)OC(=O)NCC3=CSC=N3 Chemical compound C1CNCCC12CC(C2)OC(=O)NCC3=CSC=N3 GLSUNYRWHLQJSV-UHFFFAOYSA-N 0.000 description 1
- XBDQNWJUMZZFIT-UHFFFAOYSA-N CNC(=O)c1cc(COC(=O)NC2CC3(C2)CCN(C3)c2cc(ccn2)C(F)(F)F)on1 Chemical compound CNC(=O)c1cc(COC(=O)NC2CC3(C2)CCN(C3)c2cc(ccn2)C(F)(F)F)on1 XBDQNWJUMZZFIT-UHFFFAOYSA-N 0.000 description 1
- HGQHAMWSSDOHJI-UHFFFAOYSA-N CNC(=O)c1cc(COC(=O)NC2CC3(C2)CCN(C3)c2ccc(Br)cn2)on1 Chemical compound CNC(=O)c1cc(COC(=O)NC2CC3(C2)CCN(C3)c2ccc(Br)cn2)on1 HGQHAMWSSDOHJI-UHFFFAOYSA-N 0.000 description 1
- ZWRVFXNACYSHRY-UHFFFAOYSA-N CNC(OC(CC12CCNCC1)C2C(C=CC1=C2)=NC1=CC=C2F)=O Chemical compound CNC(OC(CC12CCNCC1)C2C(C=CC1=C2)=NC1=CC=C2F)=O ZWRVFXNACYSHRY-UHFFFAOYSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 235000006810 Caesalpinia ciliata Nutrition 0.000 description 1
- 241000059739 Caesalpinia ciliata Species 0.000 description 1
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 1
- 108050007331 Cannabinoid receptor Proteins 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010008120 Cerebral ischaemia Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010008748 Chorea Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 208000006313 Delayed Hypersensitivity Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 208000014094 Dystonic disease Diseases 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- CWYNVVGOOAEACU-UHFFFAOYSA-N Fe2+ Chemical compound [Fe+2] CWYNVVGOOAEACU-UHFFFAOYSA-N 0.000 description 1
- 201000004311 Gilles de la Tourette syndrome Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000001718 Immediate Hypersensitivity Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-O Methylammonium ion Chemical compound [NH3+]C BAVYZALUXZFZLV-UHFFFAOYSA-O 0.000 description 1
- 208000019695 Migraine disease Diseases 0.000 description 1
- 208000019022 Mood disease Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000008238 Muscle Spasticity Diseases 0.000 description 1
- HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- ABDKYAVKHSMJAZ-UHFFFAOYSA-N NC(=O)c1cc(COC(=O)NC2CC3(C2)CCN(CC3)c2nccc(n2)C(F)(F)F)on1 Chemical compound NC(=O)c1cc(COC(=O)NC2CC3(C2)CCN(CC3)c2nccc(n2)C(F)(F)F)on1 ABDKYAVKHSMJAZ-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- 206010061876 Obstruction Diseases 0.000 description 1
- 206010030043 Ocular hypertension Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- STSCVKRWJPWALQ-UHFFFAOYSA-N TRIFLUOROACETIC ACID ETHYL ESTER Chemical compound CCOC(=O)C(F)(F)F STSCVKRWJPWALQ-UHFFFAOYSA-N 0.000 description 1
- 102000011040 TRPV Cation Channels Human genes 0.000 description 1
- 108010062740 TRPV Cation Channels Proteins 0.000 description 1
- 208000000323 Tourette Syndrome Diseases 0.000 description 1
- 208000016620 Tourette disease Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- BHGTXSVVOLFDCO-UHFFFAOYSA-N [3-(methylcarbamoyl)-1,2-oxazol-5-yl]methyl n-[7-(6-chloroquinolin-2-yl)-7-azaspiro[3.5]nonan-2-yl]carbamate Chemical compound O1N=C(C(=O)NC)C=C1COC(=O)NC1CC2(CCN(CC2)C=2N=C3C=CC(Cl)=CC3=CC=2)C1 BHGTXSVVOLFDCO-UHFFFAOYSA-N 0.000 description 1
- JGCBDDGMARGEHT-UHFFFAOYSA-N [6-[4-(trifluoromethyl)pyrimidin-2-yl]-6-azaspiro[2.5]octan-2-yl]carbamic acid Chemical compound OC(=O)NC1CC11CCN(C=2N=C(C=CN=2)C(F)(F)F)CC1 JGCBDDGMARGEHT-UHFFFAOYSA-N 0.000 description 1
- BSSXITMPTLOOQU-UHFFFAOYSA-N [6-[5-(4-fluorophenyl)pyridin-2-yl]-6-azaspiro[3.4]octan-2-yl]methylcarbamic acid Chemical compound C1C(CNC(=O)O)CC21CN(C=1N=CC(=CC=1)C=1C=CC(F)=CC=1)CC2 BSSXITMPTLOOQU-UHFFFAOYSA-N 0.000 description 1
- GGVJUWTVDLISHI-UHFFFAOYSA-N [7-[5-(4-fluorophenyl)pyridin-2-yl]-7-azaspiro[3.5]nonan-2-yl] methanesulfonate Chemical compound C1C(OS(=O)(=O)C)CC21CCN(C=1N=CC(=CC=1)C=1C=CC(F)=CC=1)CC2 GGVJUWTVDLISHI-UHFFFAOYSA-N 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 150000001350 alkyl halides Chemical class 0.000 description 1
- 125000002947 alkylene group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 206010002022 amyloidosis Diseases 0.000 description 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 1
- 238000012466 analgesic assay Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 125000005418 aryl aryl group Chemical group 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 208000013355 benign neoplasm of brain Diseases 0.000 description 1
- 206010004398 benign neoplasm of skin Diseases 0.000 description 1
- MRPJBKSNZXBKSF-UHFFFAOYSA-N benzyl 2-amino-7-azaspiro[3.5]nonane-7-carboxylate Chemical compound C1C(N)CC21CCN(C(=O)OCC=1C=CC=CC=1)CC2 MRPJBKSNZXBKSF-UHFFFAOYSA-N 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 238000005460 biophysical method Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- PZALNPYXGJKFQI-UHFFFAOYSA-N butyl 2-ethyloctanoate Chemical compound CCCCCCC(CC)C(=O)OCCCC PZALNPYXGJKFQI-UHFFFAOYSA-N 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- KXZJHVJKXJLBKO-UHFFFAOYSA-N chembl1408157 Chemical compound N=1C2=CC=CC=C2C(C(=O)O)=CC=1C1=CC=C(O)C=C1 KXZJHVJKXJLBKO-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 208000012601 choreatic disease Diseases 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000006165 cyclic alkyl group Chemical group 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 201000003146 cystitis Diseases 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical group C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000010118 dystonia Diseases 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002745 epiphysis Anatomy 0.000 description 1
- WCUWEJPFJTURKL-UHFFFAOYSA-N ethyl 5-[(4-nitrophenoxy)carbonyloxymethyl]-1,2-oxazole-3-carboxylate Chemical compound O1N=C(C(=O)OCC)C=C1COC(=O)OC1=CC=C([N+]([O-])=O)C=C1 WCUWEJPFJTURKL-UHFFFAOYSA-N 0.000 description 1
- MEVQJXLITCVXKL-UHFFFAOYSA-N ethyl 5-[[2-[(2-methylpropan-2-yl)oxycarbonyl]-2-azaspiro[3.3]heptan-6-yl]carbamoyloxymethyl]-1,2-oxazole-3-carboxylate Chemical compound O1N=C(C(=O)OCC)C=C1COC(=O)NC1CC2(CN(C2)C(=O)OC(C)(C)C)C1 MEVQJXLITCVXKL-UHFFFAOYSA-N 0.000 description 1
- UKLQBWLOPBPABR-UHFFFAOYSA-N ethyl N-(7-azaspiro[3.5]nonan-2-yl)carbamate Chemical compound C(C)OC(NC1CC2(C1)CCNCC2)=O UKLQBWLOPBPABR-UHFFFAOYSA-N 0.000 description 1
- SYEZLFKDDBJIDL-UHFFFAOYSA-N ethyl N-[7-(5-bromopyridin-2-yl)-7-azaspiro[3.5]nonan-2-yl]carbamate Chemical compound C(C)OC(NC1CC2(C1)CCN(CC2)C1=NC=C(C=C1)Br)=O SYEZLFKDDBJIDL-UHFFFAOYSA-N 0.000 description 1
- NNSJTYUMLAKSMM-UHFFFAOYSA-N ethyl N-[7-[5-(2-methylpropyl)pyridin-2-yl]-7-azaspiro[3.5]nonan-2-yl]carbamate Chemical compound C(C)OC(NC1CC2(C1)CCN(CC2)C1=NC=C(C=C1)CC(C)C)=O NNSJTYUMLAKSMM-UHFFFAOYSA-N 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 108010046094 fatty-acid amide hydrolase Proteins 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 206010027599 migraine Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- OKDQKPLMQBXTNH-UHFFFAOYSA-N n,n-dimethyl-2h-pyridin-1-amine Chemical compound CN(C)N1CC=CC=C1 OKDQKPLMQBXTNH-UHFFFAOYSA-N 0.000 description 1
- 208000027831 neuroepithelial neoplasm Diseases 0.000 description 1
- 208000029986 neuroepithelioma Diseases 0.000 description 1
- 208000021722 neuropathic pain Diseases 0.000 description 1
- RJMUSRYZPJIFPJ-UHFFFAOYSA-N niclosamide Chemical compound OC1=CC=C(Cl)C=C1C(=O)NC1=CC=C([N+]([O-])=O)C=C1Cl RJMUSRYZPJIFPJ-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- FATBGEAMYMYZAF-KTKRTIGZSA-N oleamide Chemical compound CCCCCCCC\C=C/CCCCCCCC(N)=O FATBGEAMYMYZAF-KTKRTIGZSA-N 0.000 description 1
- FATBGEAMYMYZAF-UHFFFAOYSA-N oleicacidamide-heptaglycolether Natural products CCCCCCCCC=CCCCCCCCC(N)=O FATBGEAMYMYZAF-UHFFFAOYSA-N 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 201000003774 sarcomatosis Diseases 0.000 description 1
- DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 201000002859 sleep apnea Diseases 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 208000018198 spasticity Diseases 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 201000005671 spondyloarthropathy Diseases 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- XQOGZNOEXSAKIZ-UHFFFAOYSA-N tert-butyl 2-(phenylmethoxycarbonylamino)-6-azaspiro[2.5]octane-6-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11C(NC(=O)OCC=2C=CC=CC=2)C1 XQOGZNOEXSAKIZ-UHFFFAOYSA-N 0.000 description 1
- DICPJODHTVCFGU-UHFFFAOYSA-N tert-butyl 2-amino-7-azaspiro[3.5]nonane-7-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11CC(N)C1 DICPJODHTVCFGU-UHFFFAOYSA-N 0.000 description 1
- SIMIIXFMGJYGLR-UHFFFAOYSA-N tert-butyl 2-oxo-7-azaspiro[3.5]nonane-7-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCC11CC(=O)C1 SIMIIXFMGJYGLR-UHFFFAOYSA-N 0.000 description 1
- WJDUCDSPGKNBBW-UHFFFAOYSA-N tert-butyl 6-amino-2-azaspiro[3.3]heptane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC11CC(N)C1 WJDUCDSPGKNBBW-UHFFFAOYSA-N 0.000 description 1
- UMXXHZDEAZUQKZ-UHFFFAOYSA-N tert-butyl 6-hydroxy-2-azaspiro[3.3]heptane-2-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CC11CC(O)C1 UMXXHZDEAZUQKZ-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- PVFOMCVHYWHZJE-UHFFFAOYSA-N trichloroacetyl chloride Chemical compound ClC(=O)C(Cl)(Cl)Cl PVFOMCVHYWHZJE-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical class [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0900493A FR2941696B1 (fr) | 2009-02-05 | 2009-02-05 | Derives d'azaspiranyl-alkylcarbamates d'heterocycles a 5 chainons, leur preparation et leur application en therapeutique |
| PCT/FR2010/050183 WO2010089510A2 (fr) | 2009-02-05 | 2010-02-04 | Dérivés d'azaspiranyl-alkylcarbamates d'hétérocycles à 5 chaînons, leur préparation et leur application en thérapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2011008308A true MX2011008308A (es) | 2011-11-02 |
Family
ID=41037747
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2011008308A MX2011008308A (es) | 2009-02-05 | 2010-02-04 | Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparacion y su aplicacion en terapeutica. |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8889702B2 (https=) |
| EP (1) | EP2393809B1 (https=) |
| JP (1) | JP5586632B2 (https=) |
| KR (1) | KR20110117215A (https=) |
| CN (1) | CN102369200B (https=) |
| AR (1) | AR075247A1 (https=) |
| AU (1) | AU2010212235B2 (https=) |
| BR (1) | BRPI1007456A2 (https=) |
| CA (1) | CA2751481C (https=) |
| CO (1) | CO6362007A2 (https=) |
| EA (1) | EA201171000A1 (https=) |
| FR (1) | FR2941696B1 (https=) |
| IL (1) | IL214390A0 (https=) |
| MA (1) | MA33104B1 (https=) |
| MX (1) | MX2011008308A (https=) |
| SG (1) | SG173557A1 (https=) |
| TN (1) | TN2011000331A1 (https=) |
| TW (1) | TW201039823A (https=) |
| UY (1) | UY32423A (https=) |
| WO (1) | WO2010089510A2 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011085216A2 (en) | 2010-01-08 | 2011-07-14 | Ironwood Pharmaceuticals, Inc. | Use of faah inhibitors for treating parkinson's disease and restless legs syndrome |
| US20130224151A1 (en) | 2010-03-31 | 2013-08-29 | United States Of America | Use of FAAH Inhibitors for Treating Abdominal, Visceral and Pelvic Pain |
| US9822129B2 (en) | 2012-03-02 | 2017-11-21 | Genentech, Inc. | Amido spirocyclic amide and sulfonamide derivatives |
| JP6099753B2 (ja) * | 2012-10-03 | 2017-03-22 | アドビナス セラピューティクス リミテッド | スピロ環化合物、その組成物及びその医薬応用 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| WO2015107494A1 (en) | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -(triazin-3-yi_/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| ES2699351T3 (es) | 2014-01-17 | 2019-02-08 | Novartis Ag | Derivados de 1-piridazin/triazin-3-il-piper(-azina)/idina/pirolidina y composiciones de las mismas para inhibir la actividad de SHP2 |
| EP3310779B1 (en) | 2015-06-19 | 2019-05-08 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
| WO2016203405A1 (en) | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| US10287266B2 (en) | 2015-06-19 | 2019-05-14 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
| WO2017160925A1 (en) * | 2016-03-16 | 2017-09-21 | Kalyra Pharmaceuticals, Inc. | Analgesic compounds |
| WO2017216706A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| CA3048340A1 (en) | 2017-01-10 | 2018-07-19 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| EP4335848A3 (en) | 2017-03-13 | 2024-06-19 | Lundbeck La Jolla Research Center, Inc. | Dual magl and faah inhibitors |
| JP7257387B2 (ja) | 2017-08-29 | 2023-04-13 | ハー・ルンドベック・アクチエゼルスカベット | スピロ環化合物並びにその作製及び使用方法 |
| CN116574105B (zh) * | 2018-09-27 | 2025-10-10 | 深圳微芯生物科技股份有限公司 | 具有吲哚胺-2,3-双加氧酶抑制活性的喹啉衍生物 |
| KR20250005229A (ko) | 2022-05-04 | 2025-01-09 | 하. 룬드벡 아크티에셀스카브 | 모노아실글리세롤 리파제 억제제로서 1,1,1,3,3,3-헥사플루오로프로판-2-일 (s)-1-(피리다진-3-일카르바모일)-6 아자스피로[2.5]옥탄-6-카르복실레이트의 결정질 형태 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0678335B2 (ja) | 1991-06-19 | 1994-10-05 | ファイザー・インコーポレーテッド | アザスピロキノロン化合物、その製法および抗菌組成物 |
| US6518423B1 (en) | 1996-08-09 | 2003-02-11 | Eisai Co., Ltd. | Benzopiperidine derivatives |
| AU755361B2 (en) | 1998-02-19 | 2002-12-12 | Eisai R&D Management Co., Ltd. | Phthalazine derivatives and remedies for erectile dysfunction |
| FR2816938B1 (fr) | 2000-11-22 | 2003-01-03 | Sanofi Synthelabo | Derives de 3-aroylindole, leur procede de preparation et les compositions pharmaceutiques en contenant |
| JP2003246780A (ja) | 2001-12-17 | 2003-09-02 | Eisai Co Ltd | 含窒素芳香環化合物の製造方法 |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| FR2843964B1 (fr) * | 2002-08-29 | 2004-10-01 | Sanofi Synthelabo | Derives de dioxane-2-alkylcarbamates, leur preparation et leur application en therapeutique |
| EA010267B1 (ru) * | 2002-10-07 | 2008-06-30 | Те Риджентс Оф Те Юниверсити Оф Калифорния | Модуляция тревоги через блокаду гидролиза анандамида |
| FR2854633B1 (fr) * | 2003-05-07 | 2005-06-24 | Sanofi Synthelabo | Derives de piperidinyl-et piperazinyl-alkylcarbamates, leur preparation et leur application en therapeutique |
| FR2866885B1 (fr) * | 2004-02-26 | 2007-08-31 | Sanofi Synthelabo | Derives de piperidinylalkylcarbamates, leur prepation et leur application en therapeutique |
| FR2885364B1 (fr) * | 2005-05-03 | 2007-06-29 | Sanofi Aventis Sa | Derives d'alkyl-, alkenyl-et alkynylcarbamates, leur preparation et leur application en therapeutique |
| WO2008013834A1 (en) | 2006-07-24 | 2008-01-31 | Gilead Sciences, Inc., | Bisfuranyl protease inhibitors |
| TW200831080A (en) * | 2006-12-15 | 2008-08-01 | Irm Llc | Compounds and compositions as inhibitors of cannabinoid receptor 1 activity |
| WO2008124085A2 (en) | 2007-04-03 | 2008-10-16 | Exelixis, Inc. | Methods of using combinations of mek and jak-2 inhibitors |
| FR2934265B1 (fr) * | 2008-07-23 | 2010-07-30 | Sanofi Aventis | Derives de carbamates d'alkylthiazoles, leur preparation et leur application en therapeutique |
| US20100113465A1 (en) * | 2008-10-30 | 2010-05-06 | Pfizer Inc. | 7-azaspiro[3.5]nonane-7-carboxamide compounds |
-
2009
- 2009-02-05 FR FR0900493A patent/FR2941696B1/fr not_active Expired - Fee Related
-
2010
- 2010-02-04 US US13/145,926 patent/US8889702B2/en not_active Expired - Fee Related
- 2010-02-04 CN CN201080014506.8A patent/CN102369200B/zh not_active Expired - Fee Related
- 2010-02-04 MA MA34149A patent/MA33104B1/fr unknown
- 2010-02-04 EA EA201171000A patent/EA201171000A1/ru unknown
- 2010-02-04 KR KR1020117020496A patent/KR20110117215A/ko not_active Withdrawn
- 2010-02-04 JP JP2011548754A patent/JP5586632B2/ja not_active Expired - Fee Related
- 2010-02-04 MX MX2011008308A patent/MX2011008308A/es unknown
- 2010-02-04 SG SG2011056462A patent/SG173557A1/en unknown
- 2010-02-04 AU AU2010212235A patent/AU2010212235B2/en not_active Ceased
- 2010-02-04 EP EP10708283.6A patent/EP2393809B1/fr active Active
- 2010-02-04 BR BRPI1007456-2A patent/BRPI1007456A2/pt not_active IP Right Cessation
- 2010-02-04 WO PCT/FR2010/050183 patent/WO2010089510A2/fr not_active Ceased
- 2010-02-04 CA CA2751481A patent/CA2751481C/fr not_active Expired - Fee Related
- 2010-02-05 TW TW099103578A patent/TW201039823A/zh unknown
- 2010-02-05 UY UY0001032423A patent/UY32423A/es not_active Application Discontinuation
- 2010-02-05 AR ARP100100315A patent/AR075247A1/es not_active Application Discontinuation
-
2011
- 2011-07-05 TN TN2011000331A patent/TN2011000331A1/fr unknown
- 2011-08-01 IL IL214390A patent/IL214390A0/en unknown
- 2011-08-05 CO CO11099134A patent/CO6362007A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20110117215A (ko) | 2011-10-26 |
| US8889702B2 (en) | 2014-11-18 |
| AU2010212235B2 (en) | 2016-06-09 |
| SG173557A1 (en) | 2011-09-29 |
| CA2751481A1 (fr) | 2010-08-12 |
| JP2012516881A (ja) | 2012-07-26 |
| WO2010089510A2 (fr) | 2010-08-12 |
| CN102369200A (zh) | 2012-03-07 |
| EP2393809A2 (fr) | 2011-12-14 |
| FR2941696B1 (fr) | 2011-04-15 |
| UY32423A (es) | 2010-09-30 |
| CN102369200B (zh) | 2015-05-20 |
| TN2011000331A1 (fr) | 2013-03-27 |
| CO6362007A2 (es) | 2012-01-20 |
| BRPI1007456A2 (pt) | 2019-04-16 |
| CA2751481C (fr) | 2017-05-23 |
| US20110319381A1 (en) | 2011-12-29 |
| WO2010089510A3 (fr) | 2010-09-30 |
| JP5586632B2 (ja) | 2014-09-10 |
| EP2393809B1 (fr) | 2014-04-30 |
| AU2010212235A1 (en) | 2011-08-25 |
| IL214390A0 (en) | 2011-09-27 |
| AR075247A1 (es) | 2011-03-16 |
| EA201171000A1 (ru) | 2012-02-28 |
| FR2941696A1 (fr) | 2010-08-06 |
| TW201039823A (en) | 2010-11-16 |
| MA33104B1 (fr) | 2012-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2011008308A (es) | Derivados de azaspiranil-alquilcarbamatos de heterociclos de 5 eslabones, su preparacion y su aplicacion en terapeutica. | |
| AU2009274355B2 (en) | Alkyl thiazole carbamate derivatives, preparation thereof, and use thereof as FAAH enzyme inhibitors | |
| EA038428B1 (ru) | Новое соединение в качестве ингибитора аутотоксина и содержащая его фармацевтическая композиция | |
| AU2006287976A1 (en) | Novel diazaspiroalkanes and their use for treatment of CCR8 mediated diseases | |
| KR102793119B1 (ko) | 키나제 억제제로서의 인다졸 카르복스아미드 | |
| CN107949384A (zh) | 毒蕈碱激动剂 | |
| JP2009539848A (ja) | 新規ピペラジン、医薬組成物、およびその使用方法 | |
| AU2010247212B2 (en) | 5-membered heterocyclic compound cyclopenta[c]pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof | |
| TW202045498A (zh) | 作為法尼醇x受體調節劑之經取代雙環化合物 | |
| JP5560287B2 (ja) | アルキル−複素環のカルバメート誘導体、これらの調製およびこれらの使用 | |
| US12479820B2 (en) | Pyridin-3-yl derivatives | |
| EP3802517A1 (en) | Alkoxy-substituted pyridinyl derivatives as lpa1 receptor antagonists and their use in the treatment of fibrosis | |
| EP4463452B1 (en) | C-myc mrna translation modulators and uses thereof in the treatment of cancer | |
| AU2011208418A1 (en) | Alkyl-heterocycle carbamate derivatives, their preparation and their therapeutic application |